DeepHealth

What DeepHealth does

DeepHealth is a global AI-powered health informatics company and wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), founded around 2015–2017 and headquartered in Somerville, Massachusetts with additional operations in Los Angeles, Paris (via the Gleamer acquisition), and Bengaluru. The company develops and deploys machine learning solutions across the radiology continuum, anchored by DeepHealth OS — a cloud-native operating system that unifies imaging data, clinical informatics, and AI capabilities into personalized workspaces for radiologists. Its portfolio is organized into two categories: Enterprise Imaging (Diagnostic Suite, Operations Suite, and TechLive remote scanning) and Population Health (Breast, Prostate, Chest, Neuro, and Thyroid Suites), spanning 26 FDA-authorized devices and 22 CE-marked products across 75+ clinical indications.

The company serves hospital systems, diagnostic imaging centers, and national screening programs — including NHS England's Lung Cancer Screening Program — across more than 50 countries, with the largest installed footprint (~435 imaging centers, 12M+ annual exams) being RadNet's own network. DeepHealth generates revenue primarily through SaaS subscriptions, OEM licensing arrangements (notably with GE HealthCare for global mammography and ultrasound distribution), and quote-based enterprise contracts with health systems. Its go-to-market combines direct enterprise field sales with strategic OEM embedded distribution. The company has grown aggressively through acquisitions, most notably the €230M Gleamer SAS transaction in March 2026, and pursues regulatory clearances across both US and EU markets to support global commercialization.

The business model is anchored by AI-first clinical evidence, including a Nature Health-published study demonstrating a 21.6% increase in breast cancer detection rate across 579,000 women, a 42% reduction in MR room closure hours via TechLive, and 97% diagnostic sensitivity in prostate cancer detection. Distribution leverage is provided by GE HealthCare as a flagship OEM partner embedding DeepHealth AI into mammography and ultrasound hardware worldwide. Combined entity ARR is projected to approach or exceed $140M by the end of 2026, supported by Gleamer's projected ~$30M ARR contribution and over 90% ARR CAGR achieved between 2022 and 2025.

Name

DeepHealth

Legal name

DeepHealth, Inc.

Website

https://deep.health

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

DeepHealth is a global AI-powered radiology health informatics company and wholly owned subsidiary of RadNet, Inc., providing AI-driven imaging, informatics, and clinical workflow solutions to hospital systems, diagnostic imaging centers, and national screening programs across 50+ countries.

Ownership category

akta.pro rank

Product category

Radiology AI Software

NAICS

Software Publishers (513210), Computer Systems Design and Related Services (54151)

SIC

Services-Health Services (8000)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Medical Imaging AI (HDAAAEAH), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD), Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC), Radiology Reporting, Dictation & Structured Reporting (HLACALAF)

Keywords

• Radiology AI software
• Clinical AI solutions
• Medical imaging analytics
• Healthcare informatics platform
• Cancer detection AI

Headquarters

HQ city

Belmont

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. SaaS/Software Subscriptions: DeepHealth operates primarily as a SaaS business model offering AI-powered radiology solutions on subscription basis. Gleamer, now part of DeepHealth, achieved over 90% ARR CAGR from 2022-2025 and is on track for ~$30M ARR in 2026. Combined entity targeting ARR approaching or exceeding $140M by end of 2026.
2. AI-Powered Workflow Solutions: Revenue from AI-powered clinical and operational solutions including Diagnostic Suite, Operations Suite, Breast Suite, and other specialty suites deployed across imaging networks
3. Platform Licensing: Technology licensing through partnerships such as GE HealthCare collaboration where DeepHealth AI is integrated into GE mammography and ultrasound systems for global distribution

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

DeepHealth develops and sells a cloud-native AI-powered radiology software platform (DeepHealth OS) that unifies imaging, informatics, and AI across the radiology continuum. The company offers Enterprise Imaging solutions (Diagnostic Suite, Operations Suite, TechLive) for diagnostic workflow orchestration, and Population Health suites (Breast, Prostate, Chest, Neuro, Thyroid) for large-scale screening and diagnostic programs. Products are delivered primarily as SaaS subscriptions to hospitals, imaging centers, and national screening programs, and are also embedded in OEM partner hardware such as GE HealthCare mammography systems.

Product overview

DeepHealth is a global AI-powered health informatics company and wholly owned subsidiary of RadNet, offering a comprehensive portfolio of radiology AI solutions. The core offering is the DeepHealth OS, a cloud-native operating system that unifies imaging, informatics, and AI across the radiology continuum. Built on this platform are two main solution categories: Enterprise Imaging (Diagnostic Suite, Operations Suite, TechLive) providing foundational AI-powered informatics for diagnostic workflows and operations; and Population Health (Breast Suite, Prostate Suite, Chest Suite, Neuro Suite, Thyroid Suite) providing end-to-end AI-powered solutions for large-scale diagnostic and screening programs. DeepHealth has also acquired multiple companies including Gleamer, Kheiron Medical, CIMAR UK, and Alpha RT to expand its capabilities. The company serves 800+ clinical sites globally with demonstrated clinical impact including 21% increase in breast cancer detection rates.

Differentiator

Problem solved

Functional benefit

Brands

• DeepHealth OS: Cloud-native operating system that unifies data across clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum.
• Diagnostic Suite
• Operations Suite
• TechLive
• Breast Suite
• Prostate Suite
• Chest Suite
• Neuro Suite
• Thyroid Suite
• Reporting Pro
• SmartMammo

Products and services

• DeepHealth OS Cloud-native operating system that unifies imaging, informatics, and AI across the radiology continuum, serving as the foundational platform that personalizes AI-powered workspaces for radiologists and connects all DeepHealth solutions.
• Diagnostic Suite Unified diagnostic workspace providing PACS functionality, enhanced viewer, advanced image management, and smart interpretation capability for radiologists in hospital and imaging center environments.
• Operations Suite Unified workspace for smart operations with RIS functionality, real-time workflow management, and streamlined operations across imaging facilities. First deployed at Wichita Radiological Group on a five-year contract.
• TechLive Multi-modality remote acquisition and collaboration platform enabling certified technologists to remotely operate MR, CT, PET/CT, and ultrasound scanners from a consolidated interface. FDA-cleared and CE-marked.
• Breast Suite End-to-end collection of modular AI-powered applications for breast cancer screening and detection including ProFound Pro for AI-powered cancer detection, automatic density assessments, breast cancer risk assessment, and breast arterial calcification assessment.
• Prostate Suite Enhanced prostate cancer detection AI solution compatible with leading fusion biopsy systems. FDA 510(k) cleared and CE-marked.
• Chest Suite AI-powered enhanced nodule detection, reporting, and patient management solution for chest imaging that supports lung cancer screening programs.
• Neuro Suite AI solution for assessing and monitoring neurodegenerative changes including Brain Health and Brain Age solutions with CE Mark approval.
• Thyroid Suite AI-powered end-to-end solution for thyroid ultrasound imaging, integrated with GE HealthCare's ultrasound portfolio.
• Reporting Pro AI-powered radiology reporting solution integrating speech recognition, clinical AI findings, measurements, and AI-generated impressions into a single workflow for automated radiology reporting.
• Gleamer AI Suite Radiology AI portfolio from the acquired Gleamer SAS brand, spanning musculoskeletal, breast, lung, and neurologic indications with FDA-cleared and CE-marked devices.
• BAC Assessment & Mammo Dx FDA 510(k) cleared AI tools — Breast Arterial Calcification Assessment detects cardiovascular disease risk during routine mammograms, and Mammo Dx compares prior and current exams to improve cancer detection.

Quantifiable outcome

• 21.6% increase in breast cancer detection rate compared to standard 3D mammography
• +6 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability9 records

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• GE HealthCareflagshipStrategic or Co-development Partner · 16 April 2026Expanded mammography collaboration integrating DeepHealth's Breast Suite AI with GE HealthCare's Senographe Pristina and Pristina Via mammography systems. Partnership began in 2024, expanded in 2025-2026 to include ProFound Pro, Safeguard Review, and second-reader workflow. A large U.S. study demonstrated 21% increase in breast cancer detection rate with AI-driven workflow. GE distributes DeepHealth AI globally alongside their mammography systems.
• RagaAIcoreTechnology or Integration · 2 December 2025Partnership to develop AI agents that streamline radiology workflows and improve operational efficiency. Collaboration aims to create scalable, reliable AI solutions that are HIPAA-aligned and FDA-ready, focusing on automating healthcare operations.
• GE HealthCare Ultrasound PartnershipcoreStrategic or Co-development Partner · 20 November 2025Expanded partnership integrating DeepHealth's Thyroid Suite and TechLive remote scanning solution with GE HealthCare's ultrasound portfolio, extending AI-powered imaging across multiple modalities.
• TeraReconcoreTechnology or Integration · 1 July 2025Strategic collaboration to scale deployment of DeepHealth solutions. TeraRecon provides advanced visualization and imaging informatics capabilities supporting DeepHealth's AI-powered radiology solutions.
• CARPL.aicoreTechnology or Integration · 1 July 2025Strategic collaboration to scale deployment of DeepHealth solutions. CARPL.ai provides an AI integration platform supporting interoperability of DeepHealth's clinical AI solutions.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Aidoc: Aidoc is a closely comparable clinical-AI platform for radiology that orchestrates triage and workflow AI across multiple modalities (CT, MRI, X-ray). It competes head-to-head with DeepHealth OS for enterprise imaging-network contracts and shares the same hospital-system GTM motion.
• Viz.ai: Viz.ai is a clinical AI company specializing in imaging workflow and care coordination, most notably for stroke and other time-sensitive conditions. It overlaps with DeepHealth's Chest Suite, Neuro Suite, and broader orchestration thesis for AI-driven radiology workflows in large hospital systems.
• Qure.ai: Qure.ai develops FDA- and CE-cleared AI for chest CT, head CT, and chest X-ray with a global footprint similar to DeepHealth's Gleamer business. It is a direct competitor in lung and neuro AI indications and competes for the same emerging-market screening-program budgets.
• Lunit: Lunit (now incorporating Volpara) is a breast and chest X-ray AI specialist with FDA-cleared and CE-marked products, directly competing with DeepHealth's Breast Suite and Chest Suite. It serves similar screening-program customers and has comparable peer-reviewed clinical evidence.
• RapidAI: RapidAI provides AI-powered imaging analysis for stroke, aneurysm, and pulmonary embolism, similar to DeepHealth's Neuro and Chest Suites. It targets the same large hospital and teleradiology customers and competes on AI workflow orchestration in acute care.

Broad incumbents

• Siemens Healthineers: Siemens Healthineers operates AI-Rad Companion, a broad radiology AI suite embedded across its installed PACS/RIS and modality base. As an incumbent imaging OEM with global distribution, it competes with DeepHealth's enterprise imaging offerings and could in-source AI to displace partners.
• GE HealthCare: GE HealthCare is both DeepHealth's flagship distribution partner (Edison platform, Senographe Pristina, ultrasound) and a potential competitor via its own AI capabilities. It is highly comparable as the global mammography and ultrasound OEM that defines the channel through which DeepHealth AI reaches customers.
• Philips Health Systems: Philips delivers IntelliSpace AI and a broad radiology informatics portfolio, providing overlapping AI and workflow capabilities to hospital systems. It competes with DeepHealth's Diagnostic and Operations Suites in the enterprise imaging market.

Emerging players

• Therapixel: Therapixel focuses on breast imaging AI (MammoScreen 2.0 with FDA clearance and CE mark), directly overlapping with DeepHealth's ProFound Pro and SmartMammo products in the mammography AI segment. It is a smaller specialist competitor in breast cancer screening AI.
• Annalise.ai: Annalise.ai provides comprehensive multi-modality radiology AI (chest X-ray, CT, MR) with broad clinical indications, comparable in scope to Gleamer's portfolio. It is an emerging competitor targeting similar hospital and imaging-center customers across multiple geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/DeepHealth
• LinkedInlinkedin.com/company/deephealth

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeepHealth